Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity

Evaluation of 5-Fluorouracil Pharmacokinetics in Cancer Patients with a C.1905+1G>A Mutation in DPYD by Means of a Bayesian Limited Sampling Strategy

(2012) André B. P. van Kuilenburg et al.   CLINICAL PHARMACOKINETICS

Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis

(2012) Barbara Anne Jennings et al.   Pharmacogenetics and Genomics

A Polymorphism in the Cytidine Deaminase Promoter Predicts Severe Capecitabine-Induced Hand-Foot Syndrome

(2011) D. Caronia et al.   CLINICAL CANCER RESEARCH

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

(2011) M. J. Deenen et al.   CLINICAL CANCER RESEARCH

Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity

(2011) Ursula Amstutz et al.   PHARMACOGENOMICS

Methylenetetrahydrofolate Reductase Polymorphism (677 C>T) Predicts Long Time to Progression in Metastatic Colon Cancer Treated with 5-Fluorouracil and Folinic Acid

(2010) Omar Castillo-Fernández et al.   ARCHIVES OF MEDICAL RESEARCH

DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity

(2010) Chen Guang Yang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity

(2010) André B. P. van Kuilenburg et al.   HUMAN GENETICS

MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer

(2009) S. Afzal et al.   ANNALS OF ONCOLOGY

Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer

(2009) M Gusella et al.   BRITISH JOURNAL OF CANCER

Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients

(2009) Julie Fidlerova et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients

(2009) Aathavan Loganayagam et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation

(2009) Elena De Mattia et al.   EUROPEAN JOURNAL OF CANCER

Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial

(2009) Michael S. Braun et al.   JOURNAL OF CLINICAL ONCOLOGY

Thymidylate synthase gene variations: predictive and prognostic markers

(2009) G. Lurje et al.   MOLECULAR CANCER THERAPEUTICS

Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment

(2009) Ursula Amstutz et al.   PHARMACOGENOMICS

Candidate mechanisms for capecitabine-related hand–foot syndrome

(2008) Gérard Milano et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile

(2008) Cedric Mercier et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphisms and Toxicity to Capecitabine in Advanced Colorectal Cancer Patients

(2008) R. Sharma et al.   CLINICAL CANCER RESEARCH

A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression

(2008) N. Ribelles et al.   CURRENT DRUG METABOLISM

Predicting Fluorouracil Toxicity: Can We Finally Do It?

(2008) Hany H. Ezzeldin et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group

(2008) Matthias Schwab et al.   JOURNAL OF CLINICAL ONCOLOGY

Strong Association of a Common Dihydropyrimidine Dehydrogenase Gene Polymorphism with Fluoropyrimidine-Related Toxicity in Cancer Patients

(2008) Eva Gross et al.   PLoS One